Please assess the completion status of the following clinical trial:

Trial Title: Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA:~In order to be eligible for this study, patients must meet ALL the 3 Inclusion criteria and NONE of the Exclusion criteria.~1. Acute STEMI defined as chest pain (or equivalent) with an onset within 12 hours and ECG evidence of ST segment elevation (\>1 mm) in 2 or more anatomically contiguous leads that is new or presumably new~2. Planned or completed coronary angiogram for potential intervention~3. Age\>21~EXCLUSION CRITERIA:~* Inability to give informed consent~* Pregnancy~* Preexisting congestive heart failure (American Heart Association/American College of Cardiology class C-D, New York Heart Association III-IV)~* Preexisting severe left ventricular dysfunction (EF\<20%)~* Preexisting severe valvular heart disease~* Active infections (acute or chronic) - excluding Hepatitis C Virus (HCV)+ with undetectable RNA~* Recent (\<14 days) or active use of anti-inflammatory drugs (not including non-steroidal anti-inflammatory drugs \[NSAIDs\] or corticosteroids used for IV dye allergy only)~* Chronic inflammatory disease (including but not limited to rheumatoid arthritis, systemic lupus erythematosus)~* Active malignancy - excluding carcinoma in situ \[any organ\] and non-melanoma skin cancer~* Anticipated need for cardiac surgery~* Neutropenia (absolute neutrophil count\<1,800/mm3)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Anakinra (standard dose) (Type: EXPERIMENTAL): Anakinra 100 mg daily for 14 days
- Anakinra (high dose) (Type: EXPERIMENTAL): Anakinra 100 mg twice daily for 14 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).